Omotuyi Olaposi Idowu, Nash Oyekanmi, Enejoh Ojochenemi Aladi, Oribamise Eunice Iyanuoluwa, Adelakun Niyi Samuel
Chemogenomics Research Unit, Department of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Ondo State, Nigeria.
Chemo-Genomics Research Institute, Afe Babalola University, Ado Ekiti, Ekiti State, Nigeria.
Toxicol Rep. 2020 Oct 8;7:1421-1427. doi: 10.1016/j.toxrep.2020.10.006. eCollection 2020.
Nephropathy is a serious complication comorbid with a number of life-threatening diseases such as diabetes. Flavonoids are well known cytoprotective phytochemicals. Here, nephropathy associated with streptozotocin (STZ) treatment in experimental animals was challenged by flavonoids (CoF) isolated from Experimental animals were divided into control (n = 5), STZ (40 . n = 5) and STZ-CoF (CoF = 30 n = 7) groups. Blood urea nitrogen (BUN) and serum creatinine (SC) levels were quantified using ELISA. Kidney function, inflammatory marker, and antioxidant gene expression levels were also evaluated using reverse-transcription and polymerase chain reaction protocols. Histological assessment was also performed using Haematoxylin and Eosin (H&E) staining protocols. CoF improved kidney function by restoring BUN/SC levels to pre-STZ treatment states. KIM-1, TNF-α, and MCP-1 but not TNF-R and IL-10 genes were significantly downregulated in STZ-CoF treated group in comparison with STZ-treated group (p < 0.05). Anti-oxidant genes (GPx-1, CAT) significantly (p < 0.05 vs. control) upregulated in STZ-treatment did not respond to CoF treatment. STZ treatment associated Bowman's space enlargement, thickened basement membrane, and glomerulosclerosis were completely reversed in STZ-CoF group. Finally, CoF has demonstrable anti-nephropathic via downregulation of proinflammatory genes and may represent new management option in clinical nephropathy.
肾病是一种严重的并发症，常与糖尿病等多种危及生命的疾病并发。黄酮类化合物是众所周知的具有细胞保护作用的植物化学物质。在此，从[具体来源未提及]分离出的黄酮类化合物（CoF）对实验动物中与链脲佐菌素（STZ）治疗相关的肾病进行了挑战。实验动物被分为对照组（n = 5）、STZ组（40mg/kg，n = 5）和STZ-CoF组（CoF = 30mg/kg，n = 7）。使用酶联免疫吸附测定法对血尿素氮（BUN）和血清肌酐（SC）水平进行定量。还使用逆转录和聚合酶链反应方案评估肾功能、炎症标志物和抗氧化基因表达水平。也使用苏木精和伊红（H&E）染色方案进行组织学评估。CoF通过将BUN/SC水平恢复到STZ治疗前的状态来改善肾功能。与STZ治疗组相比，STZ-CoF治疗组中KIM-1、TNF-α和MCP-1基因显著下调，但TNF-R和IL-10基因未下调（p < 0.05）。STZ治疗中显著上调（与对照组相比，p < 0.05）的抗氧化基因（GPx-1、CAT）对CoF治疗无反应。STZ治疗相关的鲍曼氏间隙扩大、基底膜增厚和肾小球硬化在STZ-CoF组中完全逆转。最后，CoF通过下调促炎基因具有明显的抗肾病作用，可能代表临床肾病的新治疗选择。
